Lificiguat
Lificiguat structure
|
Common Name | Lificiguat | ||
|---|---|---|---|---|
| CAS Number | 170632-47-0 | Molecular Weight | 304.342 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 522.2±50.0 °C at 760 mmHg | |
| Molecular Formula | C19H16N2O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 269.6±30.1 °C | |
|
VAV3 mediates resistance to breast cancer endocrine therapy.
Breast Cancer Res. 16(3) , R53, (2014) Endocrine therapies targeting cell proliferation and survival mediated by estrogen receptor α (ERα) are among the most effective systemic treatments for ERα-positive breast cancer. However, most tumors initially responsive to these therapies acquire resistanc... |
|
|
Stimulation of the cardiac myocyte Na+-K+ pump due to reversal of its constitutive oxidative inhibition.
Am. J. Physiol. Cell Physiol. 309 , C239-50, (2015) Protein kinase C can activate NADPH oxidase and induce glutathionylation of the β1-Na(+)-K(+) pump subunit, inhibiting activity of the catalytic α-subunit. To examine if signaling of nitric oxide-induced soluble guanylyl cyclase (sGC)/cGMP/protein kinase G ca... |
|
|
The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma.
Cancer Lett. 370 , 279-85, (2015) Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease with high mortality. Treatments, which can result in significant morbidity, have not substantially changed in three decades. The second messenger cyclic GMP (cGMP), which targets protein k... |
|
|
YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.
Br. J. Pharmacol. 171(17) , 4010-25, (2014) YC-1 exhibits potent anticancer activity via numerous actions in many cancer cell lines. Hence, we investigated the in vivo antitumour efficacy of YC-1 in an MDA-MB-468 xenograft model and elucidated the mechanism of down-regulation of enhancer of zeste homol... |
|
|
The HIF-1 inhibitor YC-1 decreases reactive astrocyte formation in a rodent ischemia model.
Am. J. Transl. Res. 7 , 751-60, (2015) Astrocytes become reactive after central nervous system injury, re-expressing glial fibrillary acidic protein (GFAP), vascular endothelial growth factor (VEGF), and nestin. Hypoxia-inducible transcription factor alpha (HIF-1α) is an important transcription fa... |
|
|
Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling.
Oncotarget 7 , 8172-83, (2016) One of the requirements for tumor development is blood supply, most often driven by hypoxia-induced angiogenesis. Hypoxia induces the stabilization of hypoxia-inducible factor-1 alpha (HIF-1α), which induces expression of an angiogenic factor, vascular endoth... |
|
|
Proximal tubule sphingosine kinase-1 has a critical role in A1 adenosine receptor-mediated renal protection from ischemia.
Kidney Int. 82(8) , 878-91, (2012) Renal ischemia-reperfusion injury is a major cause of acute kidney injury. We previously found that renal A(1) adenosine receptor (A(1)AR) activation attenuated multiple cell death pathways including necrosis, apoptosis, and inflammation. Here, we tested whet... |
|
|
Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Oncotarget 6 , 44579-92, (2016) Anti-angiogenesis is currently considered as one of the major antitumor strategies for its protective effects against tumor emergency and later progression. The anti-diabetic drug metformin has been demonstrated to significantly inhibit tumor angiogenesis bas... |
|
|
YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition.
Chin. J. Cancer 31 , 248-56, (2012) 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), the hypoxia-inducible factor-1 alpha (HIF-1α) inhibitor, suppresses tumor proliferation and metastasis by down-regulating HIF-1α expression under hypoxic conditions. Our previous studies demonstrated tha... |
|
|
Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
Biochem. Biophys. Res. Commun. 455(3-4) , 332-8, (2014) Insulin-like growth factor 1 receptor (IGF1R) is expressed in many types of solid tumors including non-small cell lung cancer (NSCLC), and enhanced activation of IGF1R is thought to reflect cancer progression. Epithelial-mesenchymal transition (EMT) has been ... |